Tilray (NASDAQ:TLRY) Shares Up 0.4% – What’s Next?

Tilray Inc (NASDAQ:TLRYGet Free Report) shares traded up 0.4% during trading on Tuesday . The stock traded as high as $1.25 and last traded at $1.21. 10,968,820 shares were traded during trading, a decline of 57% from the average session volume of 25,766,971 shares. The stock had previously closed at $1.20.

Analysts Set New Price Targets

Separately, Roth Mkm lowered their price target on shares of Tilray from $2.00 to $1.75 and set a “neutral” rating on the stock in a research note on Friday, October 11th.

Get Our Latest Stock Analysis on Tilray

Tilray Price Performance

The stock has a market cap of $1.05 billion, a price-to-earnings ratio of -4.30 and a beta of 2.08. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.57 and a current ratio of 2.47. The company has a 50-day simple moving average of $1.45 and a two-hundred day simple moving average of $1.66.

Tilray (NASDAQ:TLRYGet Free Report) last released its earnings results on Thursday, October 10th. The company reported ($0.04) earnings per share for the quarter, meeting the consensus estimate of ($0.04). Tilray had a negative net margin of 26.79% and a negative return on equity of 2.00%. The business had revenue of $200.00 million during the quarter, compared to analysts’ expectations of $218.70 million. During the same period last year, the business earned ($0.10) earnings per share. The firm’s revenue was up 13.0% on a year-over-year basis. As a group, equities research analysts forecast that Tilray Inc will post -0.14 EPS for the current year.

Insider Buying and Selling

In other Tilray news, CFO Carl A. Merton purchased 26,000 shares of the business’s stock in a transaction on Friday, November 15th. The stock was acquired at an average price of $1.36 per share, with a total value of $35,360.00. Following the acquisition, the chief financial officer now directly owns 26,000 shares of the company’s stock, valued at $35,360. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 0.87% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Tilray

Several institutional investors and hedge funds have recently modified their holdings of the stock. Ferguson Wellman Capital Management Inc. acquired a new position in shares of Tilray in the third quarter valued at approximately $26,000. Signature Estate & Investment Advisors LLC bought a new position in Tilray during the 2nd quarter worth $29,000. Jeppson Wealth Management LLC bought a new stake in shares of Tilray in the second quarter valued at about $33,000. Vanguard Capital Wealth Advisors acquired a new position in shares of Tilray in the second quarter valued at about $34,000. Finally, Pallas Capital Advisors LLC bought a new position in Tilray during the second quarter worth about $37,000. 9.35% of the stock is currently owned by institutional investors and hedge funds.

Tilray Company Profile

(Get Free Report)

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.

Read More

Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.